Trial Profile
Phase II Study of Panitumumab in Combination With Irinotecan for Malignant Gliomas.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Panitumumab (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 04 Dec 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Sep 2010 Planned end date changed from Feb 2011 to Sep 2012 as reported by ClinicalTrials.gov.